RU2014148879A - Methods for influencing PRP gene expression - Google Patents
Methods for influencing PRP gene expression Download PDFInfo
- Publication number
- RU2014148879A RU2014148879A RU2014148879A RU2014148879A RU2014148879A RU 2014148879 A RU2014148879 A RU 2014148879A RU 2014148879 A RU2014148879 A RU 2014148879A RU 2014148879 A RU2014148879 A RU 2014148879A RU 2014148879 A RU2014148879 A RU 2014148879A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- prp gene
- influencing
- antisense oligonucleotide
- methods
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ воздействия на экспрессию гена PRP в клетках пациента, включающий: приведение в контакт указанных клеток с одной или несколькими миРНК, специфичными для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности указанного гена.2. Способ по п. 1, где экспрессию понижают.3. Композиция, содержащая одну или более миРНК, специфичных для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности гена PRP.4. Способ лечения заболевания, связанного с геном PRP, включающий введение пациенту эффективной дозы одной или нескольких миРНК специфичных для антисмыслового олигонуклеотида, с последовательностью, по меньшей мере, на 70% идентичной последовательности гена PRP.1. A method of influencing the expression of a PRP gene in a patient’s cells, comprising: contacting said cells with one or more siRNAs specific for an antisense oligonucleotide, with a sequence of at least 70% identical sequence to the specified gene. The method of claim 1, wherein the expression is reduced. A composition comprising one or more siRNAs specific for an antisense oligonucleotide, with a sequence of at least 70% identical to the sequence of the PRP gene. 4. A method of treating a disease associated with the PRP gene, comprising administering to the patient an effective dose of one or more siRNAs specific for the antisense oligonucleotide, with a sequence of at least 70% identical sequence of the PRP gene.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014148879A RU2014148879A (en) | 2014-12-04 | 2014-12-04 | Methods for influencing PRP gene expression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014148879A RU2014148879A (en) | 2014-12-04 | 2014-12-04 | Methods for influencing PRP gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014148879A true RU2014148879A (en) | 2016-06-27 |
Family
ID=56195377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014148879A RU2014148879A (en) | 2014-12-04 | 2014-12-04 | Methods for influencing PRP gene expression |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2014148879A (en) |
-
2014
- 2014-12-04 RU RU2014148879A patent/RU2014148879A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891192A1 (en) | MEANS AND METHODS OF TREATMENT OF MYOPATHIES ASSOCIATED WITH TITIN AND OTHER TITINOPATHIES | |
BR112017004349A2 (en) | globin gene therapy for treatment of hemoglobinopathies | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
EA201791624A1 (en) | COMPOUNDS TO IMPROVE SPLISING of mRNA | |
AR101312A1 (en) | COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON | |
EA201591543A1 (en) | COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS | |
MX2015012176A (en) | Methods of using zscan4 for rejuvenating human cells. | |
TR201818825T4 (en) | LNCRNAS FOR THE TREATMENT AND DIAGNOSIS OF CARDIAC HYPERTROPHY | |
NI201600070A (en) | AUTOTAXIN TETRAYCLIC INHIBITORS | |
MX2017008462A (en) | Methods of using smad7 antisense oligonucleotides. | |
EA201790563A1 (en) | APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY | |
BR112018008931A2 (en) | "compounds for treating hypoproliferative disorders" | |
BR112018009745A8 (en) | heterocyclic compounds for the treatment of disease | |
CY1122708T1 (en) | OXA-DIAZASPIRE COMPOUNDS WITH ACTION AGAINST PAIN | |
MY194135A (en) | Treatment and diagnosis of inflammatory disorders | |
RU2014148879A (en) | Methods for influencing PRP gene expression | |
BR112017011513A2 (en) | treatment of eye conditions using progenitor cells | |
RU2014148258A (en) | Methods for influencing ADA gene expression | |
RU2014148877A (en) | Methods for influencing BRCA1 gene expression | |
RU2014145910A (en) | Methods for influencing APOE gene expression | |
RU2014145911A (en) | Methods for influencing BRCA2 gene expression | |
RU2014142756A (en) | Methods for influencing D4DR gene expression | |
RU2014144701A (en) | Methods for influencing TER1 gene expression | |
RU2014142757A (en) | Method for influencing TCF gene expression | |
RU2014144093A (en) | Methods for influencing CRE gene expression |